{"organizations": [], "uuid": "bbb2f6ab17d22410405b3f809b43c84f223963ea", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180517.html", "section_title": "Archive News &amp; Video for Thursday, 17 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-syndax-announces-updated-results-f/brief-syndax-announces-updated-results-from-phase-2-encore-601-trial-of-entinostat-in-combination-with-keytruda-idUSASC0A2QS", "country": "US", "domain_rank": 408, "title": "BRIEF-Syndax Announces Updated Results From Phase 2 Encore 601 Trial Of Entinostat In Combination With Keytruda®", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.128, "site_type": "news", "published": "2018-05-17T19:13:00.000+03:00", "replies_count": 0, "uuid": "bbb2f6ab17d22410405b3f809b43c84f223963ea"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-syndax-announces-updated-results-f/brief-syndax-announces-updated-results-from-phase-2-encore-601-trial-of-entinostat-in-combination-with-keytruda-idUSASC0A2QS", "ord_in_thread": 0, "title": "BRIEF-Syndax Announces Updated Results From Phase 2 Encore 601 Trial Of Entinostat In Combination With Keytruda®", "locations": [], "entities": {"persons": [], "locations": [{"name": "nsclc", "sentiment": "none"}], "organizations": [{"name": "syndax pharmaceuticals inc", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 17 (Reuters) - Syndax Pharmaceuticals Inc:\n* SYNDAX ANNOUNCES UPDATED RESULTS FROM PHASE 2 ENCORE 601 TRIAL OF ENTINOSTAT IN COMBINATION WITH KEYTRUDA® (PEMBROLIZUMAB)\n* SYNDAX PHARMACEUTICALS INC - POTENTIAL REGISTRATION PATHWAY IDENTIFIED IN NSCLC; NEXT TRIAL ANTICIPATED TO COMMENCE BY END OF 2018\n* SYNDAX PHARMACEUTICALS INC - CONFIRMED OBJECTIVE RESPONSES WITH COMBINATION REGIMEN HAVE BEEN OBSERVED ACROSS ALL COHORTS IN PHASE 2 TRIAL Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-17T19:13:00.000+03:00", "crawled": "2018-05-18T19:49:33.037+03:00", "highlightTitle": ""}